Safety and Efficacy of Upper Respiratory Tract Probiotic Biohalo23 for Acute Respiratory Tract Infections in Children
Objective:To evaluate the safety and efficacy of upper respiratory tract probiotic Biohalo23 for acute respiratory tract infection(ARTI)in children.Methods:A total of 40 children with ARTI treated in a hospital in June 2023 were selected and divided into control group and observation group by random number table,with 20 patients in each group.The control group was given conventional treatment,and the observation group was sublingually given Bactoblis®,tablets containing bioactive compounds and probiotic bacteria as tableting candy,in addition to the treatment given in the control group,and intervention was continuously provided for 7 days,with a 14-day follow-up.The duration of ARTI,medication,changes in microbiota and adverse reactions were analyzed in the two groups.Results:Within 7 days,the rate of antipyretic medication in the observation group was lower than that in the control group(P<0.05).Within 7 days and 21 days,the duration of ARTI and the number of days on antimicrobial and antiviral medication in the observation group was shorter than that in the control group(P<0.05).With respect to microbiota,the upper respiratory tract microbiota was more stable and the richness of microbiota at genus level was higher in the observation group as compared with the control group.There were significant differences in the composition of microbiota between the two groups.At the family level,the abundance of Lactobacteriaceae in the observation group was higher than that in the control group;At the genus level,the abundance of Lactobacillus and Weissella was higher,while the abundance of Eikenella was lower in the observation group as compared with the control group.During the study,no adverse reactions occurred in pediatric patients of either group.Conclusion:Upper respiratory tract probiotic Biohalo23 can help regulate the steady state of upper respiratory tract microbiota,reduce the colonization of pernicious bacteria,shorten the duration of ARTI in children and reduce the use of antimicrobial,demonstrating great application value.
upper respiratory tract probioticacute respiratory tract infectionantimicrobialsteady state of upper respiratory tract microbiotaadverse reaction
国家科技期刊平台
NSTL
万方数据
